Click here to get full coverage on Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade

Cogent Biosciences Stock Surged by Positive Pivotal Trial Results  StocksToTrade

Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade

Click here to get full coverage on Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat

Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT  MarketBeat

Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat

Click here to get full coverage on Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Yahoo Finance

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress  Yahoo Finance

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Yahoo Finance

Click here to get full coverage on Cogent Biosciences’ Clinical Trials Propel Stock with Promising Data - timothysykes.com

Cogent Biosciences’ Clinical Trials Propel Stock with Promising Data  timothysykes.com

Cogent Biosciences’ Clinical Trials Propel Stock with Promising Data - timothysykes.com

Click here to get full coverage on The Technical Signals Behind (COGT) That Institutions Follow - news.stocktradersdaily.com

The Technical Signals Behind (COGT) That Institutions Follow  news.stocktradersdaily.com

The Technical Signals Behind (COGT) That Institutions Follow - news.stocktradersdaily.com

Click here to get full coverage on COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Nasdaq

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know  Nasdaq

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Nasdaq

Click here to get full coverage on COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Zacks Investment Research

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know  Zacks Investment Research

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Zacks Investment Research

Click here to get full coverage on Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - Sahm

Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib  Sahm

Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - Sahm

Click here to get full coverage on A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results - simplywall.st

A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results  simplywall.st

A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results - simplywall.st

Click here to get full coverage on Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $48 - 富途牛牛

Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $48  富途牛牛

Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $48 - 富途牛牛

Click here to get full coverage on COGT Boom: Is It Time to Cash In? - StocksToTrade

COGT Boom: Is It Time to Cash In?  StocksToTrade

COGT Boom: Is It Time to Cash In? - StocksToTrade

Click here to get full coverage on Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Yahoo Finance

Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So  Yahoo Finance

Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Yahoo Finance

Click here to get full coverage on Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat

Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT)  MarketBeat

Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat

Click here to get full coverage on Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - simplywall.st

Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib  simplywall.st

Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - simplywall.st

Click here to get full coverage on Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance

Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans  Yahoo Finance

Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance

Click here to get full coverage on Cogent Biosciences’ Stock Climbs with Landmark Clinical Trial Results - StocksToTrade

Cogent Biosciences’ Stock Climbs with Landmark Clinical Trial Results  StocksToTrade

Cogent Biosciences’ Stock Climbs with Landmark Clinical Trial Results - StocksToTrade

Click here to get full coverage on Birchview Capital LP Buys New Stake in Cogent Biosciences, Inc. $COGT - MarketBeat

Birchview Capital LP Buys New Stake in Cogent Biosciences, Inc. $COGT  MarketBeat

Birchview Capital LP Buys New Stake in Cogent Biosciences, Inc. $COGT - MarketBeat

Click here to get full coverage on Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? - Yahoo Finance

Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed?  Yahoo Finance

Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Redmile Group LLC Sells 1,767,986 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat

Redmile Group LLC Sells 1,767,986 Shares of Cogent Biosciences, Inc. $COGT  MarketBeat

Redmile Group LLC Sells 1,767,986 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat

Click here to get full coverage on Cogent Biosciences (COGT): Assessing Valuation After a 119% One-Day Surge and 316% YTD Gain - Yahoo Finance

Cogent Biosciences (COGT): Assessing Valuation After a 119% One-Day Surge and 316% YTD Gain  Yahoo Finance

Cogent Biosciences (COGT): Assessing Valuation After a 119% One-Day Surge and 316% YTD Gain - Yahoo Finance

Click here to get full coverage on COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success  Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

Click here to get full coverage on Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus

Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham |  GuruFocus

Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus

Click here to get full coverage on Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering - Stock Titan

Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering  Stock Titan

Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering - Stock Titan

Click here to get full coverage on Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - Yahoo Finance

Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating  Yahoo Finance

Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - Yahoo Finance

Click here to get full coverage on Cogent Biosciences (NASDAQ: COGT) reports 46% ORR vs 26% in PEAK trial in second-line GIST - Stock Titan

Cogent Biosciences (NASDAQ: COGT) reports 46% ORR vs 26% in PEAK trial in second-line GIST  Stock Titan

Cogent Biosciences (NASDAQ: COGT) reports 46% ORR vs 26% in PEAK trial in second-line GIST - Stock Titan

Click here to get full coverage on Cogent Biosciences Stock Soars on Positive Trial Results - timothysykes.com

Cogent Biosciences Stock Soars on Positive Trial Results  timothysykes.com

Cogent Biosciences Stock Soars on Positive Trial Results - timothysykes.com

Click here to get full coverage on Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation - Nasdaq

Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation  Nasdaq

Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation - Nasdaq

Click here to get full coverage on COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More  Quiver Quantitative

COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Click here to get full coverage on Cogent Biosciences (NASDAQ: COGT) prices 9,677,420 shares at $31; plus convertible notes - Stock Titan

Cogent Biosciences (NASDAQ: COGT) prices 9,677,420 shares at $31; plus convertible notes  Stock Titan

Cogent Biosciences (NASDAQ: COGT) prices 9,677,420 shares at $31; plus convertible notes - Stock Titan

Click here to get full coverage on Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial - Yahoo Finance

Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial  Yahoo Finance

Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial - Yahoo Finance

Click here to get full coverage on Why Is Cogent Biosciences Stock (COGT) Up 115% Today? - TipRanks

Why Is Cogent Biosciences Stock (COGT) Up 115% Today?  TipRanks

Why Is Cogent Biosciences Stock (COGT) Up 115% Today? - TipRanks

Click here to get full coverage on Cogent Bio surges on trial data for lead drug (COGT:NASDAQ) - Seeking Alpha

Cogent Bio surges on trial data for lead drug (COGT:NASDAQ)  Seeking Alpha

Cogent Bio surges on trial data for lead drug (COGT:NASDAQ) - Seeking Alpha

Click here to get full coverage on Why Cogent Biosciences (COGT) Is Up 18.9% After Positive Phase 3 GIST Trial Results - simplywall.st

Why Cogent Biosciences (COGT) Is Up 18.9% After Positive Phase 3 GIST Trial Results  simplywall.st

Why Cogent Biosciences (COGT) Is Up 18.9% After Positive Phase 3 GIST Trial Results - simplywall.st

Click here to get full coverage on Biotech Catapults 119% On A First-In-20-Years Development - Investor's Business Daily

Biotech Catapults 119% On A First-In-20-Years Development  Investor's Business Daily

Biotech Catapults 119% On A First-In-20-Years Development - Investor's Business Daily

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year High - Here's What Happened - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year High - Here's What Happened  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year High - Here's What Happened - MarketBeat

Click here to get full coverage on Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?  Yahoo Finance

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Click here to get full coverage on Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Cogent Biosciences: Moving Forward (NASDAQ:COGT) - Seeking Alpha

Cogent Biosciences: Moving Forward (NASDAQ:COGT)  Seeking Alpha

Cogent Biosciences: Moving Forward (NASDAQ:COGT) - Seeking Alpha

Click here to get full coverage on Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT) - Seeking Alpha

Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT)  Seeking Alpha

Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT) - Seeking Alpha

Click here to get full coverage on Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC - MarketBeat

Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC  MarketBeat

Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC - MarketBeat

Click here to get full coverage on Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT) - Seeking Alpha

Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT)  Seeking Alpha

Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT) - Seeking Alpha

Click here to get full coverage on Biggest stock movers Monday: RUM, MTSR, COGT, OSCR, and more - Seeking Alpha

Biggest stock movers Monday: RUM, MTSR, COGT, OSCR, and more  Seeking Alpha

Biggest stock movers Monday: RUM, MTSR, COGT, OSCR, and more - Seeking Alpha

Click here to get full coverage on Cogent Biosciences (COGT) Reports Positive Results from APEX Par - GuruFocus

Cogent Biosciences (COGT) Reports Positive Results from APEX Par  GuruFocus

Cogent Biosciences (COGT) Reports Positive Results from APEX Par - GuruFocus

Click here to get full coverage on New Analyst Forecast: $COGT Given $50.0 Price Target - Quiver Quantitative

New Analyst Forecast: $COGT Given $50.0 Price Target  Quiver Quantitative

New Analyst Forecast: $COGT Given $50.0 Price Target - Quiver Quantitative

Click here to get full coverage on Breakthrough Therapy Designation: Cogent's bezuclastinib gains FDA nod, NDA submission planned by YE 2025 - Stock Titan

Breakthrough Therapy Designation: Cogent's bezuclastinib gains FDA nod, NDA submission planned by YE 2025  Stock Titan

Breakthrough Therapy Designation: Cogent's bezuclastinib gains FDA nod, NDA submission planned by YE 2025 - Stock Titan

Click here to get full coverage on Cogent Biosciences (NASDAQ: COGT) expects Phase 3 PEAK Nov and APEX Dec readouts - Stock Titan

Cogent Biosciences (NASDAQ: COGT) expects Phase 3 PEAK Nov and APEX Dec readouts  Stock Titan

Cogent Biosciences (NASDAQ: COGT) expects Phase 3 PEAK Nov and APEX Dec readouts - Stock Titan

Click here to get full coverage on Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now  Yahoo Finance

Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Cogent Biosciences Reports Positive APEX Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis, Plans NDA Submission in 2026 - Quiver Quantitative

Cogent Biosciences Reports Positive APEX Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis, Plans NDA Submission in 2026  Quiver Quantitative

Cogent Biosciences Reports Positive APEX Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis, Plans NDA Submission in 2026 - Quiver Quantitative

Click here to get full coverage on Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - Nasdaq

Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation  Nasdaq

Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - Nasdaq

Click here to get full coverage on Precision Medicine Biotech Cogent Biosciences to Present Latest Developments at Major Biopharma Conference - Stock Titan

Precision Medicine Biotech Cogent Biosciences to Present Latest Developments at Major Biopharma Conference  Stock Titan

Precision Medicine Biotech Cogent Biosciences to Present Latest Developments at Major Biopharma Conference - Stock Titan

Click here to get full coverage on Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation - Nasdaq

Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation  Nasdaq

Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation - Nasdaq

Click here to get full coverage on Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - Yahoo Finance

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock  Yahoo Finance

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - Yahoo Finance

Click here to get full coverage on Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - GlobeNewswire

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)  GlobeNewswire

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - GlobeNewswire

Click here to get full coverage on Insider Purchase: Director at $COGT Buys 2,777,777 Shares - Quiver Quantitative

Insider Purchase: Director at $COGT Buys 2,777,777 Shares  Quiver Quantitative

Insider Purchase: Director at $COGT Buys 2,777,777 Shares - Quiver Quantitative

Click here to get full coverage on Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial - GuruFocus

Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial  GuruFocus

Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial - GuruFocus

Click here to get full coverage on Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages  MarketBeat

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT - MarketBeat

Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT  MarketBeat

Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT - MarketBeat

Click here to get full coverage on Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC - MarketBeat

Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC  MarketBeat

Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC - MarketBeat

Click here to get full coverage on Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts - Yahoo Finance

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts  Yahoo Finance

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts - Yahoo Finance

Click here to get full coverage on J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating - 富途牛牛

J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating  富途牛牛

J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat

Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT  MarketBeat

Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat

Click here to get full coverage on $COGT stock is up 9% today. Here's what we see in our data. - Quiver Quantitative

$COGT stock is up 9% today. Here's what we see in our data.  Quiver Quantitative

$COGT stock is up 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Cogent's NonAdvSM Drug Trial Hits All Endpoints with 87% Response Rate, Two More Pivotal Results Coming - Stock Titan

Cogent's NonAdvSM Drug Trial Hits All Endpoints with 87% Response Rate, Two More Pivotal Results Coming  Stock Titan

Cogent's NonAdvSM Drug Trial Hits All Endpoints with 87% Response Rate, Two More Pivotal Results Coming - Stock Titan

Click here to get full coverage on New Analyst Forecast: $COGT Given $22.0 Price Target - Nasdaq

New Analyst Forecast: $COGT Given $22.0 Price Target  Nasdaq

New Analyst Forecast: $COGT Given $22.0 Price Target - Nasdaq

Click here to get full coverage on HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation - Nasdaq

HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation  Nasdaq

HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation - Nasdaq

Click here to get full coverage on Cogent Biosciences : COGT ASH 2025 Webcast FINAL - marketscreener.com

Cogent Biosciences : COGT ASH 2025 Webcast FINAL  marketscreener.com

Cogent Biosciences : COGT ASH 2025 Webcast FINAL - marketscreener.com

Click here to get full coverage on Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis  Investing News Network

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network

COGT

Price Chart

Key Statistics

Technicals

About COGT

Latest News

Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade

Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat

Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers